• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Association Between Famotidine Use and Clinical Outcomes in Patients With COVID-19: Assessment of Available Evidence.法莫替丁使用与新型冠状病毒肺炎患者临床结局之间的关联：现有证据评估
Am J Gastroenterol. 2021 Apr;116(4):848-849. doi: 10.14309/ajg.0000000000001008.
2
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.法莫替丁的使用与住院COVID-19患者临床结局改善相关：一项倾向评分匹配的回顾性队列研究。
Gastroenterology. 2020 Sep;159(3):1129-1131.e3. doi: 10.1053/j.gastro.2020.05.053. Epub 2020 May 22.
3
Famotidine Repurposing for Novel Corona Virus Disease of 2019: A Systematic Review.法莫替丁在 2019 年新型冠状病毒疾病中的再利用：系统评价。
Drug Res (Stuttg). 2021 Jul;71(6):295-301. doi: 10.1055/a-1397-6763. Epub 2021 Mar 23.
4
Famotidine and Hospitalized COVID-19 Patients: Are the Benefits True?法莫替丁与住院的新冠病毒肺炎患者：益处是真的吗？
Am J Gastroenterol. 2021 Jul 1;116(7):1561. doi: 10.14309/ajg.0000000000001217.
5
Histamine receptors and COVID-19.组胺受体与 COVID-19。
Inflamm Res. 2021 Jan;70(1):67-75. doi: 10.1007/s00011-020-01422-1. Epub 2020 Nov 18.
6
Famotidine and Mortality in Coronavirus Disease 2019.法莫替丁与2019冠状病毒病死亡率
Gastroenterology. 2021 Jul;161(1):361-362. doi: 10.1053/j.gastro.2020.12.045. Epub 2020 Dec 31.
7
Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study.质子泵抑制剂或法莫替丁的使用与重症 COVID-19 疾病：一项倾向评分匹配的全地区研究。
Gut. 2021 Oct;70(10):2012-2013. doi: 10.1136/gutjnl-2020-323668. Epub 2020 Dec 4.
8
Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis.法莫替丁的使用与 COVID-19 患者重症病程风险：一项荟萃分析
Mayo Clin Proc. 2021 May;96(5):1365-1367. doi: 10.1016/j.mayocp.2021.03.001. Epub 2021 Mar 5.
9
Does Famotidine Reduce the Risk of Progression to Severe Disease, Death, and Intubation for COVID-19 Patients? A Systemic Review and Meta-Analysis.法莫替丁能否降低新冠病毒肺炎患者进展为重症疾病、死亡及插管的风险？一项系统评价与Meta分析
Dig Dis Sci. 2021 Nov;66(11):3929-3937. doi: 10.1007/s10620-021-06872-z. Epub 2021 Feb 24.
10
In Reply-Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis.回复——法莫替丁的使用与新冠肺炎患者重症病程风险：一项荟萃分析。
Mayo Clin Proc. 2021 May;96(5):1367-1368. doi: 10.1016/j.mayocp.2021.03.002. Epub 2021 Mar 5.

本文引用的文献

1
Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19.法莫替丁对 COVID-19 住院患者临床结局的影响。
Am J Gastroenterol. 2020 Oct;115(10):1617-1623. doi: 10.14309/ajg.0000000000000832.
2
Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching.质子泵抑制剂与 COVID-19 相关的严重临床结局：一项全国性队列研究与倾向评分匹配。
Gut. 2021 Jan;70(1):76-84. doi: 10.1136/gutjnl-2020-322248. Epub 2020 Jul 30.
3
Association Between Famotidine Use and COVID-19 Severity in Hong Kong: A Territory-wide Study.香港法莫替丁使用与新冠肺炎严重程度之间的关联：一项全港性研究。
Gastroenterology. 2021 Apr;160(5):1898-1899. doi: 10.1053/j.gastro.2020.05.098. Epub 2020 Jul 16.
4
Mortality From Coronavirus Disease 2019 Increases With Unsaturated Fat and May Be Reduced by Early Calcium and Albumin Supplementation.2019年冠状病毒病导致的死亡率随不饱和脂肪增加而上升，早期补充钙和白蛋白可能降低死亡率。
Gastroenterology. 2020 Sep;159(3):1015-1018.e4. doi: 10.1053/j.gastro.2020.05.057. Epub 2020 May 27.
5
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.法莫替丁的使用与住院COVID-19患者临床结局改善相关：一项倾向评分匹配的回顾性队列研究。
Gastroenterology. 2020 Sep;159(3):1129-1131.e3. doi: 10.1053/j.gastro.2020.05.053. Epub 2020 May 22.

Association Between Famotidine Use and Clinical Outcomes in Patients With COVID-19: Assessment of Available Evidence.

作者信息

Ma Tianyi, Wu Meng

机构信息

1Department of Hepatopancreatobiliary Medicine, The Second Hospital of Jilin University, Jilin, China.

出版信息

Am J Gastroenterol. 2021 Apr;116(4):848-849. doi: 10.14309/ajg.0000000000001008.

DOI:10.14309/ajg.0000000000001008
PMID:33982973
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7553027/
Abstract
摘要